Abstract Details

Title Disease Impact and Burden in Patients with SCN2A-Related Developmental and Epileptic Encephalopathy

Topic Child Neurology and Developmental Neurology

Presentation(s) P11 - Poster Session 11 (11:45 AM-12:45 PM)

Poster/Presentation
Number 4-012

Objective Explore the burden of SCN2A-DEE on patients and caregivers using clinical data generated via a novel, patient-consented, real-world data platform.

Background SCN2A-related DEE comprises a subset of rare neurodevelopmental genetic disorders characterized by significant heterogeneity and limited understanding of disease burden and progression.

Design/Methods Real-world clinical data were extracted from patients with an SCN2A variant using Invitae’s Ciitizen platform, which employs a proprietary approach combining machine learning and expert human review to streamline generation of research-grade data from unstructured health records spanning ~10 years. Extracted data (seizure history, medications, comorbidities, developmental milestones) were classified by phenotype based on age at seizure onset, type of seizure at initial presentation, variant type and functional characterization using dynamic action potential clamp analysis.

Results

45 patients (92%) had data available for analyses. Four phenotypes were identified across three groups: early onset (EO, 33.5%), late onset (LO, 42%), and autism without epilepsy (AO, 24.5%). The LO group contained two distinct phenotypes based on age and type of seizure at onset: the first, characterized by initial seizure presentation with infantile spasms (LOIS, 20%); the second characterized by seizures other than infantile spasms and presenting later in life (LO, 22%).

Mean patient age across cohorts was 8 years (0.8–23.3), with similar percentages of males and females. Mean age at seizure onset was 5.1 days (1–44) in the EO group. 53% of patients with seizures experienced status epilepticus at least once. Mean number of medications prescribed over a patient’s lifetime was 18.1 (0–58). Patients had multiple comorbidities, with global developmental delay the most common (97%), and hypotonia, GERD, autism, and sleep disorders reported in >50%. All patients did not meet at least one critical developmental milestone.

Conclusions Using a novel real-world data platform and functional variant characterization, we provide unprecedented insight into clinical phenotypes, disease burden and treatment patterns in SCN2A-DEE.

Authors/Disclosures
Brian Pfister PRESENTER	Dr. Pfister has received personal compensation for serving as an employee of Praxis Precisions Medicines. Dr. Pfister has stock in Praxis Precision Medicines.
Kelley Del Real	Kelley Dalby has received personal compensation for serving as an employee of Praxis Precision Medicines. Kelley Dalby has stock in Praxis Precision Medicines. Kelley Dalby has stock in RogCon.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Michael S. Oldham, MD, MPH	Dr. Oldham has received personal compensation for serving as an employee of Praxis Precision Medicines.
Marcio Souza	Marcio Souza has received personal compensation for serving as an employee of Praxis Precision Medicines.
	No disclosure on file

��ɫ��

��ɫ��